PDCD1 and myelodysplastic syndrome: Based on these results, and those of multiple preclinical and clinical studies in solid tumors that cDC1 frequency and function govern responses to anti–PD-1 and other immunotherapies, we hypothesize that characteristics of this population in patients with MDS could contribute to clinical responses to immunotherapy.31